松龄血脉康胶囊用于脑梗死恢复期疗效观察

目的评价松龄血脉康胶囊用于脑梗死恢复期的临床疗效。方法109例脑梗死恢复期患者随机分为两组，对照组（54例）应用常规治疗，治疗组（55例）应用常规治疗加松龄血脉康胶囊口服。治疗前及治疗后60天分别对两组临床疗效、Barthel指数评分、血液流变学、血脂及血清c反应蛋白（CRP）进行比较。结果治疗组总显效率（70．9％）显著高于对照组（55．6％）（P〈0．01）；与对照组治疗后相比，治疗组治疗后血脂中TC、TG、HDL—C和LDL-C差异有统计学意义（P〈0．05或P〈0．01）；治疗后治疗组血清CRP、纤维蛋白原和Barthel指数与对照组差异有统计学意义（均P〈0．01）。用药后两组患者均未发现明显不适反应。结论松龄血脉康胶囊能显著改善脑梗死恢复期患者的临床疗效和日常生活能力，无不良反应，其机制可能与其调节患者血脂、改善血液流变学和减轻缺血组织的炎性反应有关。

The therapeutic mechanism of Songling Xuemaikang Capsule on the individual with cerebral infarction reconvalescent

Objective To investigate the therapeutic effect of traditional Chinese medicine,Songling Xuemaikang Capsule on the individual with cerebral infarction reconvalescent and its mechanism.Methods Patients in control group( n =54) received regularly therapy and treatment group( n =55) was treated with regularly therapy and Songling Xuemaikang Capsule for eight weeks respectively.The clinical therapeutic effeets,Barthel index,hemorheology indexes,serum lipid and C-reactive protein (CRP) were determined.Results The total clinical effective rate in treatment group and control group was 70.9％ and 55.6％ (P ＜ 0.01 ).After eight weeks treatment,the scores of Barthel Index,hemorheology indexes,the amounts of serum lipid and CRP in treatment group were improved significantly as compared to the control group ( P ＜ 0.05 or P ＜ 0.01 ).There was no severely side effect found in this trial.Conclusion Songling Xuemaikang Capsule could partly improve patients clinical outcome and life quality.The clinical efficacy of Songling Xuemaikang Capsule on the individual with cerebral infarction reconvalescent should be related to its functioning to promote the recovery of patients' blood hemorheology,and regulate serum lipid and decrease CRP level.